The blogwaves were buzzing recently with the news that tamoxifen (nolvadex), the once (and perhaps future) king of breast cancer prevention drugs, is showing legs as the years go by and studies of its long-term effects become clearer. A recent article in the British Journal of the National Cancer Institute reveals that tamoxifen reduced the incidence of breast cancer in the study group by 32% after 4 years; by 27% after 8 years; and by 39% after 13 years, a full eight years after the women in...



